Reassessing Imaging Surveillance in Diffuse Large B-Cell Lymphoma

Dr. Brian Link discusses clinical implications of the large Mayo Clinic/ University of Iowa study (ASCO abstract 8504) showing patient symptoms rather than scheduled surveillance imaging drove detection of relapses in patients with diffuse large B-cell lymphoma (DLBCL).
Source: Cancer Network - Category: Cancer & Oncology Source Type: news

Related Links:

This study aimed to determine the impact of treatment facility on overall survival outcomes in DLBCL patients stratified by IPI risk groups.MethodsThe National Cancer Database was utilized to identify patients diagnosed with DLBCL between 2004 and 2015. Patients were stratified by IPI risk score from low to high risk disease, and overall survival of those treated at academic centers were compared to those treated at non-academic centers.ResultsTreatment at academic centers was associated with a significantly improved overall survival for all DLBCL patients (108.3 months) when compared to non-academic centers (74.5 months, p
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Blood Cancer Journal, Published online: 21 November 2019; doi:10.1038/s41408-019-0256-yPrecise detection of genomic imbalances at single-cell resolution reveals intra-patient heterogeneity in Hodgkin’s lymphoma
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
ConclusionsOur study provides the first report of the severe, early reactivation of an inactive HBsAg carrier after CAR T cell therapy in DLBCL.Trial registrationChiCTR-OPN-16008526.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Infectious diseases are still a significant cause of morbidity and mortality worldwide. Despite the progress in drug development, the occurrence of microbial resistance is still a significant concern. Alternative therapeutic strategies are required for non-responding or relapsing patients. Chimeric antigen receptor (CAR) T cells has revolutionized cancer immunotherapy, providing a potential therapeutic option for patients who are unresponsive to standard treatments. Recently two CAR T cell therapies, Yescarta® (Kite Pharma/Gilead) and Kymriah® (Novartis) were approved by the FDA for the treatments of certain types ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Jamroziak Ibrutinib is the first Bruton’s tyrosine kinase (BTK) inhibitor, which showed significant clinical activity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) patients regardless of cytogenetic risk factors. Recent results of phase III clinical trials in treatment-naïve CLL patients shift the importance of the agent to frontline therapy. Nevertheless, beside its clinical efficacy, ibrutinib possesses some off-target activity resulting in ibrutinib-characteristic adverse events including bleeding diathesis and arrhythmias. Furthermore, acquired and primary resistanc...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
In conclusion, we demonstrated that MCL is an FDG-avid lymphoma and 18F-FDG-PET/CT is a useful tool for staging purpose, showing good specificity for BM and GI evaluation, but suboptimal sensitivity. EotPET/CT result was the only independent significant prognostic factor that correlated with PFS.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
As the Puget Sound region's biotech industry continues to grow, Seattle Genetics is leading the pack with its therapeutic for lymphoma on the market and two more late-stage products for bladder and breast cancer on the way. “Seattle Genetics has reached a transformational point in its history,” CEO Clay Siegall told the Business Journal. “Seattle Genetics will remain focused on making a meaningful difference in cancer patients’ lives through discovering, developing and commercializing transformative…
Source: Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Source Type: news
ConclusionOverall, our results do not support an association between the WCRF/AICR score and CLL, yet we might have been limited by statistical power and study design to detect modest associations. Further research, ideally with a prospective design, long follow-up, and including additional lymphoma subtypes, is warranted to confirm the impact of composite healthy lifestyle behaviors on lymphoma risk.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
In conclusion, TAMs increased the proportion of cancer stem cells through PTN/β-catenin pathway in lymphoma. PMID: 31737191 [PubMed]
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
Publication date: 19 November 2019Source: Cell Reports, Volume 29, Issue 8Author(s): Makoto Yamagishi, Makoto Hori, Dai Fujikawa, Takeo Ohsugi, Daisuke Honma, Nobuaki Adachi, Harutaka Katano, Tsunekazu Hishima, Seiichiro Kobayashi, Kazumi Nakano, Makoto Nakashima, Masako Iwanaga, Atae Utsunomiya, Yuetsu Tanaka, Seiji Okada, Kunihiro Tsukasaki, Kensei Tobinai, Kazushi Araki, Toshiki Watanabe, Kaoru UchimaruSummaryAlthough global H3K27me3 reprogramming is a hallmark of cancer, no effective therapeutic strategy for H3K27me3-high malignancies harboring EZH2WT/WT has yet been established. We explore epigenome and transcriptome ...
Source: Cell Reports - Category: Cytology Source Type: research
More News: Cancer | Cancer & Oncology | Lymphoma | Study